Bensalem, Amina
Cartron, Guillaume
Specks, Ulrich
Mulleman, Denis
Gyan, Emmanuel
Cornec, Divi
Desvignes, Celine
Casasnovas, Olivier
Lamy, Thierry
Leprêtre, Stéphane
Paintaud, Gilles
Ternant, David http://orcid.org/0000-0003-4020-4545
Article History
Accepted: 5 October 2021
First Online: 13 November 2021
Declarations
:
: This study was made using rituximab pharmacokinetic data belonging to the Lymphoma Study Association (France), French Innovative Leukemia Organization (FILO, France), Mayo Clinic (Rochester, MO, USA), and Tours University Hospital (Tours, France). The study in patients with diffuse large B-cell lymphoma and follicular lymphoma was funded by GELA and GOELAMS groups and F. Hoffman-La Roche Ltd (Basel, Switzerland). The study in chronic lymphocytic leukemia was funded by FILO Group and Roche SAS (Neuilly, France). The study comparing rituximab and cyclophosphamide in anti-neutrophil <u>cytoplasmic</u> autoantibody-associated vasculitis (RAVE) was supported by a grant from the National Institute of Allergy and Infectious Diseases to the Immune Tolerance Network (Grant N01-AI-15416; Protocol No. ITN021AI). Genentech, Inc. and Biogen IDEC, Inc. provided study medications and partial funding for this trial. Measurements of rituximab serum concentrations in patients with chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and rheumatoid arthritis were carried out by CePiBAc platform. CePiBAc is cofinanced by the European Union. Europe is committed to the région Centre Val-de-Loire with the European Regional Development Fund. CePiBac was partly supported by the French Higher Education and Research Ministry under the program ‘Investissements d’avenir’ Grant Agreement: LabEx MAbImprove ANR-10-LABX-53-01. Genentech, Inc. measured rituximab concentrations by the enzyme-linked immunosorbent assay for the RAVE trial.
: Guillaume Cartron received consultancy fees from Roche and Celgene, honoraria from Roche, Celgene, Jansen, Gilead, and Sanofi, and travel arrangements from Jansen, Gilead, and Sanofi. Emmanuel Gyan received research funding from Roche, is a coordinating investigator of a clinical trial supported by Roche, and received honoraria for scientific meetings organized by Roche. Olivier Casasnovas has acted as a consultant for and received honoraria from Roche, Gilead Sciences, Bristol Myers Squibb, Takeda, MSD, and AbbVie and has received research funding from Roche and Gilead. Gilles Paintaud reports grants received by his research team from Novartis, Roche Pharma, Genzyme, MSD, Chugai, and Pfizer, outside of the submitted work. Denis Mulleman reports grants from Abbvie and Nordic Pharma and consultancy fees for MSD, Novartis, UCB, and Pfizer. David Ternant reports lecture fees for Sanofi, Novartis, Amgen, and Boehringer Ingelheim. Amina Bensalem, Ulrich Specks, Divi Cornec, Céline Desvignes, Thierry Lamy, and Stéphane Leprêtre have nothing to declare.
: All studies were approved by the local ethics committee.
: Written informed consent was obtained from all patients.
: Not Applicable.
: Data and material are available upon request to the corresponding author.
: The code is available upon request to the corresponding author.
: Amina Bensalem analyzed and interpreted the data and wrote the manuscript. Guillaume Cartron designed the clinical study in patients with diffuse large B-cell lymphoma and follicular lymphoma, and contributed to materials/patients, was the principal investigator of the clinical study in patients with chronic lymphocytic leukemia, and reviewed the manuscript. Ulrich Specks was responsible for the design and coordination of the anti-neutrophil cytoplasmic antibody-associated vasculitis cohort, acquired the data, and reviewed the manuscript. Emmanuel Gyan contributed to materials/patients in the clinical study in patients with diffuse large B-cell lymphoma and follicular lymphoma, and reviewed the manuscript. Gilles Paintaud designed the study in patients with chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma, participated in data interpretation, and reviewed the manuscript. Denis Mulleman was responsible for the design and coordination of the rheumatoid arthritis cohort, acquired the data, participated in data interpretation, and reviewed the manuscript. David Ternant designed the study in patients with diffuse large B-cell lymphoma, follicular lymphoma, and rheumatoid arthritis, supervised data analysis and interpretation, participated in the writing of the manuscript, and reviewed the manuscript.